|
60 |
[2026.10.02] (주)큐브바이오, SEC Form F-4 효력발생…Nasdaq ‘Global Market’상장 예정
|
2026-10-01 |
1,017 |
|
59 |
[2025.06.23] CUBEBIO Co., Ltd. Collaborates with Korean Medical Institutions and Global Reinsurer on Pancreatic Cancer Screening Service Through Four-Party Agreement
|
2025-06-23 |
6,131 |
|
58 |
[2024.09.02] CUEBIO Signs the Merger Agreement for the Nasdaq SPAC
|
2024-09-02 |
13,413 |
|
57 |
[2024.06.26] "Diagnosing cancer in 5 minutes using urine," interview with Jaemyeong Kim, the Vice Chairman of CUBEBIO
|
2024-07-22 |
11,061 |
|
56 |
[2024.05.03] CUBEBIO Co., Ltd. signed term sheets worth KRW 850 billion with Mountain Crest Acquisition Corp. V, a NASDAQ-listed SPAC company in the U.S.
|
2024-05-03 |
12,356 |
|
55 |
[2024.04.01] CUBEBIO Co., Ltd. signs a USD 14.8Mn-worth exclusive distribution agreement for cancer screening products with the Taiwanese pharmaceutical group Taiwan Biotech Co., Ltd.
|
2024-04-01 |
10,058 |
|
54 |
[2024.01.22] CUBEBIO Co., Ltd. signed NASDAQ SPAC listing agreement
|
2024-01-22 |
23,713 |
|
53 |
[2023.09.21] CUBEBIO Co., Ltd. Attracts Investment of $46.7Mn through Technology Verification .. One step forward for US Market entry
|
2023-09-21 |
28,623 |
|
52 |
[2023.05.19] CUBEBIO's urine-based cancer screening product selected as the 'Innovative product' in Scouter Demo-day run by Public Procurement Service(PPS)
|
2023-05-19 |
21,782 |
|
51 |
[2022.02.17] CUBEBIO, selected as the new resident company at the Healthcare Innovation Park (HIP) of Seoul National University Hospital
|
2022-02-17 |
24,099 |
